Integrative Cancer Therapies最新文献

{"title":"Deepening the Framework: A TCM-Informed Perspective on Qualitative Experiences in Integrative Psycho-Oncology for Colorectal Cancer Survivors.","authors":"Mingyue Chen, Yan Han, Fenxiang Zhang","doi":"10.1177/15347354261416436","DOIUrl":"10.1177/15347354261416436","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261416436"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12847644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Herbal Medicine Is Associated With Improved Survival in Patients With Advanced Lung Cancer Receiving Standard Treatment: A Nationwide Population-Based Propensity Score Matching Study.","authors":"Kai-Yuan Hsiao, Wei-Shan Chang, Shi-Chen Ou, Hao-Ren Yao, Der-Chen Chang, Ben-Chang Shia, Ming-Chih Chen, Meng-Che Hsieh","doi":"10.1177/15347354261439131","DOIUrl":"10.1177/15347354261439131","url":null,"abstract":"<p><strong>Purpose: </strong>There is a lack of large-scale evidence regarding the prognostic impact of Chinese herbal medicine (CHM) on patients with lung cancer. This paper aimed to conduct a nationwide population-based study to investigate the role of CHM for patients with lung cancer with standard treatment.</p><p><strong>Methods: </strong>Patients diagnosed with lung cancer and treated with standard therapy between 2013 and 2015 were retrospectively identified from National Health Insurance Research Database and Taiwan Cancer Registry. Patients were classified into a CHM group and a non-CHM group based on prior medical records. Kaplan-Meier analysis was performed to estimate overall survival (OS) between each group.</p><p><strong>Results: </strong>A total of 7351 matched patients were included in the outcome analysis and comparison, with 3677 patients in the CHM cohort and 3674 patients in the non-CHM cohort. The mean age of our patients was 60.68 ± 11.26 years, and 56% of our patients were female. Our results demonstrates that patients who received CHM had significantly longer OS compared to those who did not receive CHM (HR: 0.59, 95% CI: 0.556-0.625, <i>P</i> < .0001). In subgroup analysis, survival differences were not significant for stage I-II disease, whereas OS was significantly better in the CHM group among patients with stage III-IV disease. Multivariable analysis showed CHM usage was found to significantly influence OS. The most commonly used single CHM was <i>Hedyotis diffusa</i> Willd and compound CHM was San-Zhong-Kui-Jian-Tang.</p><p><strong>Conclusion: </strong>Our nationwide population-based study suggested that CHM in conjugation with standard treatment was associated with improved survival in patients with advanced lung cancer. Integrating cancer treatment with CHM could be adopted in the treatment of lung cancer to improve prognosis.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261439131"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of a Ketogenic Diet on Cancer: Evidence From Systematic Reviews and Meta-Analyzes.","authors":"Majid Kamali, Masoomeh Ataei Kachooei, Bahareh Aminnezhad, Elham Nikoei Foshtomi, Alireza Eftekhar, Ali Shamsi-Goushki, Saeideh Mohammadi, Ali Nouri, Mohammad Esmail Akbari, Mona Zendehdel, Bita Moradi, Narjes Ashouri Mirsadeghi, Parsa Bahmani, Farnush Bakhshimoghaddam, Razieh Bahiraie, Hamid Abbasi, Saeid Doaei, Maryam Gholamalizadeh","doi":"10.1177/15347354261422756","DOIUrl":"10.1177/15347354261422756","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests that the ketogenic diet (KD) may support cancer treatment by improving metabolic parameters and reducing treatment-related side effects. This review aimed to synthesize evidence from systematic reviews and meta-analyses on the effects of ketogenic diets in cancer, focusing on metabolic outcomes, body composition, quality of life, and tumor progression. Treatment-related complications were considered as exploratory outcomes.</p><p><strong>Methods: </strong>A comprehensive review of meta-analyses were conducted following PRISMA guidelines. Databases including PubMed, Scopus, and Web of Science were searched for systematic reviews and meta-analyses exploring the effects of KD on cancer and treatment side effects. After screening 615 articles, 24 eligible reviews were examined to explore the effects of ketogenic diets on metabolism, quality of life, body composition, and cancer progression.</p><p><strong>Results: </strong>KD improved metabolic markers such as glucose and triglycerides, and showed benefits in body composition and quality of life. Evidence on treatment-related complications, including radiotherapy side effects, was limited and heterogeneous.</p><p><strong>Conclusions: </strong>KD shows promise as a safe and effective adjunctive therapy in cancer management. More evidence is needed to draw firm conclusions.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261422756"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Oncology <i>à La Française</i>. Evolution and Distinctive Features.","authors":"Benedicte Mastroianni, Violaine Forissier, Jean Lionel Bagot","doi":"10.1177/15347354261474462","DOIUrl":"10.1177/15347354261474462","url":null,"abstract":"<p><p>Integrative Oncology (IO) in France aligns with the definition proposed by the Society for Integrative Oncology, combining conventional cancer treatments with evidence-based complementary therapies within an interdisciplinary, patient-centered framework. Unlike alternative approaches, integrative therapies are used alongside standard oncological care. In France, a wide range of complementary therapies are implemented, with some-such as homeopathy and acupuncture-more widely integrated, reflecting historical use and favorable safety profiles.Over the past decade, IO has developed through diverse organizational models, including hospital-based day care programs, dedicated consultations in cancer centers, and community-based structures. These models provide access to personalized and coordinated care pathways, with no out-of-pocket cost for patients, supported by the national health insurance system or alternative funding sources. In 2023, the French Society for Integrative Oncology was established to structure and promote this approach nationwide and to foster connections with the European branch of the Society for Integrative Oncology.Compared with international models, the French approach appears distinctive in combining hospital-based and community-based structures, thereby facilitating broader accessibility while maintaining coordination with conventional care. This hybrid organization contrasts with predominantly academic models in the United States and more systematically integrated hospital-based systems in countries such as Israel.Available data and patient-reported outcomes suggest improvements in quality of life and treatment adherence. However, marked heterogeneity across programs and a predominantly observational evidence base highlight the need for controlled trials specifically designed to evaluate the particularities of integrative oncology.Overall, integrative oncology in France represents a pragmatic and evolving model that may contribute to reshaping supportive cancer care by combining accessibility, coordination, and patient-centered approaches.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261474462"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The AMICO Clinic Approach to Integrative Oncology in Breast Cancer Care: Structure and Clinical Framework From a Southern Italian Hospital.","authors":"Graziella Marino, Alexios Thodas, Carmela Cristiano, Massimo Bonucci, Marisabel Mecca, Marzia Sichetti","doi":"10.1177/15347354251413227","DOIUrl":"10.1177/15347354251413227","url":null,"abstract":"<p><p>With increasing survival rates for breast cancer (BC)-91% at 5 years and 80% at 15 years post-diagnosis-there is growing recognition of the importance of addressing long-term patient well-being. Beyond standard medical treatments, factors such as diet, psychological health, and quality of life significantly impact BC outcomes. Integrative oncology, which combines conventional oncology therapies with evidence-based complementary approaches (including nutrition, mind-body practices, and lifestyle modifications), has emerged as a patient-centered model aimed at improving symptom management, treatment adherence, and overall quality of life. This work describes the introduction of integrative oncology practices through the \"AMICO\" clinic, located within the Breast Surgery Unit at IRCCS-CROB in Rionero in Vulture, Southern Italy. As the first initiative of its kind in a public hospital in Italy, the clinic aims to provide a patient-centered approach for BC patients undergoing chemotherapy, radiation therapy, and/or breast surgery, with the mission to alleviate common side effects and improve their quality of life. During its first year of activity, the clinic has conducted joint consultations with nutritionists, organized mind-body laboratories (including Qigong sessions) and collected real-time clinical data These activities provide a foundation for the development of robust clinical databases and support a structured approach to patient-centered integrative care. By combining conventional oncology with evidence-based complementary therapies, the AMICO Clinic provides an example of a structured approach to personalization of cancer care. Ongoing and future research will further clarify the clinical value and potential benefits of integrative oncology in enhancing patient well-being.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251413227"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146207024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: <i>Ganoderma lucidum</i> Exerts an Anticancer Effect on Human Osteosarcoma Cells via Suppressing the Wnt/β-Catenin Signaling Pathway.","authors":"","doi":"10.1177/15347354261442976","DOIUrl":"10.1177/15347354261442976","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261442976"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cells <i>in vitro</i> and HT-29 cell xenograft tumor model in nude mice.","authors":"Yi-Shih Ma, Fu-Shin Chueh, Yi-Ping Huang, Shu-Fen Peng, Chao-Lin Kuo, Jaw-Chyun Chen, Fei-Ting Hsu, Kuang-Chi Lai, Yu-Jung Lin","doi":"10.1177/15347354261448871","DOIUrl":"10.1177/15347354261448871","url":null,"abstract":"<p><p>Irinotecan (IRI), a clinically used anticancer drug, is effective against various solid tumors, including colorectal cancer, but its use is limited by side effects. Triptolide (TP), an alkaloid from <i>Tripterygium wilfordii</i>, has been used to treat malignancies in China, though its combined effects with IRI on colon cancer cells are not well-documented. <i>In vitro</i>, human colon cancer HT-29 cells were treated with IRI, TP, or both combinations. Results showed that the combination of IRI and TP significantly decreased viable cell numbers more than IRI or TP alone. IRI combined with TP also led to higher Bax and lower Bcl-2 levels, as well as increased cleaved caspase-8, -9, and -3. These findings suggest that TP enhances apoptosis in HT-29 cells and may potentiate the anticancer effects of IRI by disrupting the balance of pro- and anti-apoptotic proteins, which plays a crucial role in controlling tumor cell survival. <i>In vivo</i>, HT-29 cell-xenograft nude mice were treated with IRI, TP, or both combinations for 30 days. Tumor volume and body weight were measured every 2 days, and liver and kidney functions (ALT, AST, CREA, GGT) were assessed. H&E staining of tissues revealed no significant toxicity in the heart, lungs, liver, kidneys, spleen, or small intestine, suggesting that the combination therapy does not induce major organ damage. Immunohistochemical (IHC) analysis showed that IRI combined with TP resulted in higher expression of cleaved-caspase-3, -8, and -9 compared to IRI or TP alone, indicating enhanced tumor cell apoptosis. These results suggest that TP enhances IRI's anti-cancer effects by promoting apoptosis in colon cancer cells. TP may thus serve as a potential enhancer for IRI in future colon cancer treatments, offering a novel strategy to improve therapeutic outcomes, enhance drug efficacy, and minimize side effects.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261448871"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13201951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scutellaria Barbata Water Extract Suppresses Breast Cancer Growth and Lung Metastasis by Inducing Ferroptosis.","authors":"Quanyang Liao, Yutong Wang, Xiaoyue Li, Yunzhu Dong, Yue Shu, Anlv Ren, Lu Yang, Jv Li, Xiaosan Su, Ruifen Sun","doi":"10.1177/15347354261450966","DOIUrl":"10.1177/15347354261450966","url":null,"abstract":"<p><strong>Background: </strong>Lung metastasis is the primary cause of mortality in aggressive breast cancers, particularly triple-negative breast cancer (TNBC), underscoring the urgent need for effective antimetastatic strategies.</p><p><strong>Objective: </strong>This study aimed to evaluate the efficacy, safety, and molecular mechanisms of Scutellaria barbata water extract (SBW) against breast cancer lung metastasis, with a focus on ferroptosis induction and epithelial-mesenchymal transition (EMT) inhibition.</p><p><strong>Methods: </strong>In vitro and in vivo experiments to evaluate the antitumor and antimetastatic activities of SBW. Proteomic and metabolomic analyses were performed to identify key pathways and bioactive components. Ferroptosis markers and EMT-related proteins were measured by biochemical assays and Western blotting. Arachidonic acid (AA) was validated using in vitro and in vivo functional experiments.</p><p><strong>Results: </strong>SBW dose-dependently reduced breast cancer cell viability, migration, and invasion in vitro. In vivo, SBW suppressed tumor growth and lung metastasis in 4T1 tumor-bearing mice without systemic toxicity. Proteomic analysis revealed that SBW induced ferroptosis, characterized by increased Fe^2⁺, ROS, LPO levels, and upregulation of HO-1/NCOA4, concomitant with downregulation of GPX4. SBW also inhibited EMT by reducing Twist and N-cadherin expression without affecting E-cadherin. Metabolomic profiling identified AA as a critical bioactive component. Functional validation confirmed that AA induced ferroptosis in vitro and inhibited tumor growth/metastasis in vivo.</p><p><strong>Conclusions: </strong>SBW exerts potent antimetastatic effects through dual mechanisms: induction of ferroptosis via GPX4 inhibition and suppression of EMT via Twist/N-cadherin downregulation. Arachidonic acid plays a central role in mediating ferroptosis.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261450966"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Approach of Intraneural Facilitation Versus Standard Physical Therapy for the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial.","authors":"Jamie Hankins, Mark Bussell, Lida Gharibvand, Won Jin Jeon, Dani Ran Castillo, Ellen D'Errico, Gayathri Nagaraj","doi":"10.1177/15347354251413222","DOIUrl":"10.1177/15347354251413222","url":null,"abstract":"<p><p>This study compared Intraneural Facilitation (INF^®) therapy and standard physical therapy (PT) in preventing chemotherapy-induced peripheral neuropathy (CIPN) in women with newly diagnosed breast and gynecologic cancer. Thirty-eight women undergoing platinum and/or taxane-based chemotherapy, without prior peripheral neuropathy, were randomized into INF^® therapy (n = 20) and PT (n = 18). Treatments lasted 45 minutes, twice weekly, for 6 weeks. Neuropathy severity was evaluated using the Pain Quality Assessment Scale. Assessments were at baseline, 3 weeks, 6 weeks, and 3 months post-intervention. Acceptability, burden, and satisfaction were evaluated after 6 weeks. Among 38 patients, 12 (32%) experienced CIPN, with mean pain scores remaining mild (≤3) and no pharmacotherapy required until week 6. No adverse events were reported from the interventions. The INF^® therapy arm showed significant changes in numbness (<i>F</i> = 6.030, <i>P</i> = .001, partial η² = 0.262) after week 6, while the PT arm showed significant changes in numbness (<i>Z</i> = -2.39, <i>P</i> = .017), tingling (<i>Z</i> = -2.84, <i>P</i> = .004), cramping (<i>Z</i> = -2.120, <i>P</i> = .034), surface pain (<i>Z</i> = -2.75, <i>P</i> = .006), and deep pain (<i>Z</i> = -1.99, <i>P</i> = .046) between weeks 3 and 6. Nearly 80% of patients completed chemotherapy cycles with an average relative dose intensity of 90.4% (INF^® therapy: 87.73% vs PT: 73.44%). Ninety-four percent of patients were satisfied with their care, accepted the treatments, and perceived them as a low burden. The results demonstrated that INF^® therapy and PT are feasible options for CIPN, improving treatment adherence, outcomes, and quality of life for women with newly diagnosed breast and gynecological cancers.<b>Trial Registration</b> - The study was pre-registered on ClinicalTrials.gov (NCT03272919). August 8, 2017.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251413222"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise as Precision Medicine: Targeting HER2/CD44-Driven Therapy Resistance in Breast Cancer (A Mini Review).","authors":"Fatemeh Alsadat Edalat Haghi, Maryam Koushkie Jahromi","doi":"10.1177/15347354251407216","DOIUrl":"10.1177/15347354251407216","url":null,"abstract":"<p><p>Despite advances in HER2-targeted therapies and CSC-directed agents, resistance remains a major barrier in breast cancer. Synthesize evidence for exercise as a precision strategy to disrupt HER2/CD44-driven resistance circuits. Preclinical and clinical data demonstrate that physical activity: (1) downregulates HER2/PI3K signaling via myokine-mediated pathways (IL-6/SPARC), (2) reduces CD44 through NK-dependent immune surveillance, and (3) synergizes with biologics to overcome cardiotoxicity and chemoresistance. Molecular subtype-specific exercise prescriptions are defined. Exercise reprograms the tumor-immune microenvironment to target therapy-resistant pathways, establishing a paradigm for exercise as adjuvant precision medicine.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251407216"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12775297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}